The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.50
Bid: 48.00
Ask: 49.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.083%)
Open: 48.50
High: 49.00
Low: 48.50
Prev. Close: 48.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re: Directorate Change

8 Jul 2015 17:15

RNS Number : 5491S
Cambridge Cognition Holdings PLC
08 July 2015
 

8 July 2015

 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

Re: Directorate Change

 

Further to the Company's announcement of 1 July 2015, the following information regarding the appointment of Steven John Powell, aged 53, is disclosed pursuant to paragraph (g) of Schedule Two to the AIM Rules for Companies.

 

Other directorships and partnerships held:

 

Current

Within the last 5 years

CE Bioscience Limited

Andron Pharma Limited

Chroma Therapeutics Limited

Fast Track Pharma (Holdings) Limited

Fast Track Pharma Limited

Plethora Solutions Holdings PLC

Macrotarg Limited

Plethora Solutions Limited

The Brain Tumour Charity

Plethora Therapeutics Limited

The Native Antigen Company Limited

The Urology Company Holdings Limited

The Truffaldino Partnership Limited

The Urology Company Limited

 

 

There is no further information on Dr. Powell required to be disclosed under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies.

 

 

Enquiries:

 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Michael Lewis, Chairman

Steven Powell, Chief Operating Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer

finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Geoff Nash/Simon Hicks

(Corporate Finance)

Malar Velaigam

(Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAUWSVRVNABRAR
Date   Source Headline
8th May 201411:03 amRNSResult of AGM
8th May 20147:00 amRNSAGM Statement
10th Apr 201411:41 amRNSPosting of Annual Report & Notice of AGM
2nd Apr 20147:00 amRNSDirectorate Change
14th Mar 20147:00 amRNSNesta report features Cambridge Cognition
13th Mar 20147:00 amRNSFinal Results
11th Mar 20147:00 amRNSProfessor Trevor Robbins wins 'The Brain Prize'
3rd Mar 20147:00 amRNSNew software launched for cognitive research
9th Jan 20147:00 amRNSAppointment of Director
16th Dec 20137:00 amRNSDavid Cameron References Cambridge Cognition
26th Nov 20137:00 amRNSCEO Review and Update
18th Sep 20137:00 amRNSHalf Yearly Report
14th Aug 20137:00 amRNSDirectorate Change
26th Jun 20137:00 amRNSProgress update on CANTABmobileT
18th Jun 20131:04 pmRNSHolding(s) in Company
19th Apr 20137:00 amRNSNHS Commissioning Board sets new DES for dementia
18th Apr 20137:00 amRNSAdmission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.